CapsoVision (CV) vs. The Competition Critical Contrast

CapsoVision (NASDAQ:CV) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare CapsoVision to similar companies based on the strength of its profitability, earnings, valuation, dividends, institutional ownership, risk and analyst recommendations.

Volatility and Risk

CapsoVision has a beta of -2.34, meaning that its share price is 334% less volatile than the S&P 500. Comparatively, CapsoVision’s rivals have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Earnings and Valuation

This table compares CapsoVision and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CapsoVision	$13.55 million	-$25.32 million	-13.34
CapsoVision Competitors	$1.89 billion	$136.81 million	5.76

CapsoVision’s rivals have higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CapsoVision and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1	1	2	0	2.25
CapsoVision Competitors	4290	10574	18359	830	2.46

CapsoVision currently has a consensus target price of $9.50, indicating a potential upside of 51.52%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.54%. Given CapsoVision’s higher possible upside, equities analysts plainly believe CapsoVision is more favorable than its rivals.

Insider & Institutional Ownership

40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares CapsoVision and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
CapsoVision Competitors	-304.20%	-315.07%	-22.11%

Summary

CapsoVision rivals beat CapsoVision on 10 of the 13 factors compared.

CapsoVision Company Profile

CapsoVision develops medical technology for capsule endoscopy, a method of examining the digestive tract using a swallowable camera. Its products are designed to help clinicians visualize the small intestine as part of diagnostic evaluation. The company’s CapsoCam Plus system uses a swallowable capsule with multiple cameras to capture panoramic images as it moves through the small intestine. Images are stored in the capsule and later retrieved for review using the company’s supporting hardware and software.